Mepolizumab reduced healthcare resource utilization and improved work productivity in patients with severe asthma during the REALITI-A 2-year study.

IF 1.3 4区 医学 Q3 ALLERGY
Giorgio Walter Canonica, Arnaud Bourdin, Erika Penz, Lingjiao Zhang, Peter Howarth, Rafael Alfonso-Cristancho
{"title":"Mepolizumab reduced healthcare resource utilization and improved work productivity in patients with severe asthma during the REALITI-A 2-year study.","authors":"Giorgio Walter Canonica, Arnaud Bourdin, Erika Penz, Lingjiao Zhang, Peter Howarth, Rafael Alfonso-Cristancho","doi":"10.1080/02770903.2025.2558755","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To assess the real-world impact of mepolizumab on healthcare resource utilization (HCRU) and work productivity and activity impairment (WPAI) in patients with severe asthma.</p><p><strong>Methods: </strong>Asthma-related HCRU and WPAI were assessed over 2 years in the REALITI-A study-an international, prospective, observational cohort study in adults with severe asthma newly initiating mepolizumab (100 mg subcutaneous). Secondary endpoints of the study compared the proportion of patients with HCRU use, HCRU events, and WPAI component scores 12 months before mepolizumab initiation with 24 months follow-up. The relative rates of HCRU outcomes were calculated, with a treatment policy estimand for discontinuation.</p><p><strong>Results: </strong>Patients (<i>N</i> = 822) had a mean age of 54 years and 63% were female. Hospitalization rates were reduced by 53% in the 0-12-month follow-up period (<i>p</i> < 0.001) and sustained for 24 months. The rates of asthma-related hospitalizations, emergency department visits, and outpatient visits reduced by 59-64% (<i>p</i> < 0.001) across the 24-month follow-up. The mean number of overnight hospital stays reduced from 2.4 in the pre-treatment period to 1.0 and 0.5 in the 0-12-month and 12-24-month follow-up periods, respectively. The WPAI Asthma activity impairment score was reduced from baseline by 47% and 55% at 12 and 24 months of follow-up. Overall work impairment was reduced by 62% and 74%.</p><p><strong>Conclusions: </strong>Mepolizumab treatment reduced HCRU while improving activity and productivity in patients with severe asthma over 2 years. These data provide further evidence of real-world benefits of mepolizumab and may help inform healthcare system resource allocation.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-11"},"PeriodicalIF":1.3000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02770903.2025.2558755","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To assess the real-world impact of mepolizumab on healthcare resource utilization (HCRU) and work productivity and activity impairment (WPAI) in patients with severe asthma.

Methods: Asthma-related HCRU and WPAI were assessed over 2 years in the REALITI-A study-an international, prospective, observational cohort study in adults with severe asthma newly initiating mepolizumab (100 mg subcutaneous). Secondary endpoints of the study compared the proportion of patients with HCRU use, HCRU events, and WPAI component scores 12 months before mepolizumab initiation with 24 months follow-up. The relative rates of HCRU outcomes were calculated, with a treatment policy estimand for discontinuation.

Results: Patients (N = 822) had a mean age of 54 years and 63% were female. Hospitalization rates were reduced by 53% in the 0-12-month follow-up period (p < 0.001) and sustained for 24 months. The rates of asthma-related hospitalizations, emergency department visits, and outpatient visits reduced by 59-64% (p < 0.001) across the 24-month follow-up. The mean number of overnight hospital stays reduced from 2.4 in the pre-treatment period to 1.0 and 0.5 in the 0-12-month and 12-24-month follow-up periods, respectively. The WPAI Asthma activity impairment score was reduced from baseline by 47% and 55% at 12 and 24 months of follow-up. Overall work impairment was reduced by 62% and 74%.

Conclusions: Mepolizumab treatment reduced HCRU while improving activity and productivity in patients with severe asthma over 2 years. These data provide further evidence of real-world benefits of mepolizumab and may help inform healthcare system resource allocation.

在REALITI-A为期2年的研究中,Mepolizumab降低了严重哮喘患者的医疗资源利用率并提高了工作效率。
目的:评估mepolizumab对重症哮喘患者医疗资源利用率(HCRU)、工作效率和活动障碍(WPAI)的实际影响。方法:在realti -a研究中评估哮喘相关HCRU和WPAI超过2年的时间,realti -a研究是一项国际前瞻性、观察性、队列研究,研究对象是新启动mepolizumab (100 mg皮下)的成人严重哮喘患者。该研究的次要终点比较了mepolizumab开始前12个月使用HCRU的患者比例、HCRU事件和WPAI成分评分,随访24个月。计算HCRU结果的相对比率,并对停止治疗的治疗政策进行估计。结果:822例患者平均年龄54岁,其中63%为女性。在0-12个月的随访期间,住院率降低了53% (P P结论:Mepolizumab治疗降低了HCRU,同时改善了2年以上严重哮喘患者的活动和生产力。这些数据为mepolizumab的实际益处提供了进一步的证据,并可能有助于告知医疗保健系统资源分配。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Asthma
Journal of Asthma 医学-过敏
CiteScore
4.00
自引率
5.30%
发文量
158
审稿时长
3-8 weeks
期刊介绍: Providing an authoritative open forum on asthma and related conditions, Journal of Asthma publishes clinical research around such topics as asthma management, critical and long-term care, preventative measures, environmental counselling, and patient education.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信